Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 42126573.
- Also identified by DOI 10.1158/1078-0432.CCR-26-0753.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dual PD-1/CTLA-4 inhibition improves outcomes in several cancers but remains limited by toxicity. A recent article reports the first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody, demonstrating durable responses, but dose-dependent immune-related adverse events were also observed. This commentary examines whether the bispecific format meaningfully improves the therapeutic index and considers priorities for the next phase of development.